Dr. Stephen Gitelman is a pediatric endocrinologist who serves as director of UCSF's pediatric diabetes program. He oversees the multidisciplinary team of pediatric diabetes experts who provide comprehensive care to more than 800 children, adolescents and young adults with type 1 and type 2 diabetes. His expertise includes the latest approaches to helping patients achieve optimal metabolic control, such as the insulin pump, continuous glucose sensor and novel insulin analogues.

In his research, Gitelman aims to better understand the cause for immune-mediated destruction of insulin-producing beta cells, as well as to find safe, effective ways to alter the natural course of diabetes. He serves as director for UCSF's participation in the type 1 diabetes research network TrialNet, an international project with funding from the National Institutes of Health. He is also an investigator in the Immune Tolerance Network, for which he oversees clinical trials of therapies to preserve beta cell function.

Gitelman earned an undergraduate degree at Princeton University, where he graduated summa cum laude. He completed his medical degree at the University of North Carolina at Chapel Hill. He completed a residency in pediatrics and a fellowship in pediatric endocrinology at UCSF, where he holds the Mary B. Olney, MD/KAK Distinguished Professorship in Pediatric Diabetes and Clinical Research.

  • Education

    University of North Carolina School of Medicine, MD, 1984

  • Residencies

    UCSF, Pediatrics, 1987

  • Fellowships

    UCSF, Pediatric Endocrinology, 1990

  • Board Certifications

    Pediatric Endocrinology, American Board of Pediatrics

  • Academic Title


Where I see patients (2)

    Decorative Caduceus

    Type 1 Diabetes Extension Study

    Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal...


    More about this study
    Decorative Caduceus

    Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

    The primary outcome is the time from treatment assignment to changes in glucose tolerance. The time to development of abnormal glucose tolerance or the diagnosis of type 1 diabetes will be measured to identify these changes.


    More about this study
    See all clinical trials

    Feeling at home

    From bedside bingo to therapy dogs, we're here to help kids smile and feel more like themselves.

    Visit Child Life services